NLS Pharmaceutics and Kadimastem have been granted a Hong Kong patent for cell-selection technology used in IsletRx, a stem cell-derived therapy for insulin-dependent diabetes, expanding their intellectual property protection in Asia.

NLS Pharmaceutics is launching a preclinical program to evaluate Mazindol ER as a potential treatment for fentanyl dependence, a major global health crisis. Mazindol ER targets multiple neurotransmitter systems implicated in opioid addiction, offering a non-opioid alternative.

Kadimastem has called for a special general meeting of shareholders to approve the merger with NLS Pharmaceutics. The merger aims to create a combined Nasdaq-traded biotechnology company with a robust pipeline of advanced therapies.